End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001.
Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its.
Abbott is joining the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which will use data science to predict, track and control diseases that are being amplified by climate change
Abbott and New Global Consortium Partnership Address Viral Outbreaks Caused by Climate Change streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.